---
title: "Metabolite Chemistry Reagents Market, Global Outlook and Forecast 2025-2032"
datePublished: Sat Dec 06 2025 15:14:44 GMT+0000 (Coordinated Universal Time)
cuid: cmiufq06j000102jp1smp1rbb
slug: metabolite-chemistry-reagents-market-global-outlook-and-forecast-2025-2032-1

---

# Metabolite Chemistry Reagents Market, Global Outlook and Forecast 2025-2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>The global metabolite chemistry reagents market size was valued at USD 116 million in 2024. The market is projected to grow from USD 119 million in 2025 to USD 140 million by 2032, exhibiting a CAGR of 2.7% during the forecast period.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/297445/metabolite-chemistry-reagents-market">
            https://www.24chemicalresearch.com/download-sample/297445/metabolite-chemistry-reagents-market</a></b></div><br><p>
</p><p>Metabolite chemistry reagents are specialized biochemical compounds used for the detection and analysis of metabolic reactions in vitro or in vivo. These reagents play a critical role in diagnosing metabolic disorders by measuring specific biomarkers associated with glycometabolism, amino acid metabolism, and lipid metabolism. The primary applications include diabetes monitoring, obesity research, and other metabolic syndrome-related diagnostics.</p><p>
</p><p>The market growth is driven by increasing global prevalence of metabolic disorders, with diabetes affecting over 537 million adults worldwide as of 2023. Furthermore, advancements in diagnostic technologies and rising healthcare expenditure in emerging economies are contributing to market expansion. The glycometabolism segment dominates with approximately 50% market share due to high demand for glucose monitoring reagents. Key players like Merck, Thermo Fisher Scientific, and Abbott collectively hold significant market presence, leveraging their extensive product portfolios and global distribution networks to maintain competitiveness.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Rising Prevalence of Metabolic Disorders to Accelerate Demand for Diagnostic Reagents</strong></p><p>
</p><p>The global burden of metabolic disorders such as diabetes, obesity, and dyslipidemia has reached alarming levels, with diabetes alone affecting over 537 million adults worldwide as of 2024. This epidemic drives substantial demand for metabolite chemistry reagents used in diagnostic assays. The glycated hemoglobin (HbA1c) test, which requires specialized reagents for glycometabolism analysis, has seen annual growth exceeding 8% in testing volumes as healthcare systems prioritize early detection and management of diabetes. Furthermore, the increasing adoption of point-of-care testing in clinics and pharmacies creates additional demand for reliable metabolite detection reagents that deliver rapid results.</p><p>
</p><p style="text-align:center"><strong>Advancements in Automated Clinical Chemistry Systems Boost Reagent Utilization</strong></p><p>
</p><p>Modern clinical laboratories are increasingly transitioning to fully automated chemistry analyzers that can process over 1,000 tests per hour, creating substantial demand for compatible metabolite chemistry reagents. These systems require standardized, high-purity reagents with excellent batch-to-batch consistency to maintain analytical precision. Major diagnostic companies have invested significantly in reagent formulations optimized for automated platforms, with the global clinical chemistry analyzer market projected to maintain 5.2% CAGR through 2030. The integration of artificial intelligence for result interpretation further enhances the value proposition of these advanced reagent systems.</p><p>
</p><p style="text-align:center"><strong>Growing Emphasis on Preventive Healthcare Creates New Testing Opportunities</strong></p><p>
</p><p>Healthcare systems worldwide are shifting focus from treatment to prevention, driving expanded metabolic screening programs. Annual health check-ups now routinely include multiple metabolite panels, with comprehensive metabolic panels (CMP) and lipid profiles accounting for nearly 40% of all clinical chemistry tests performed. Reagent manufacturers are responding with innovative multiparameter test solutions that reduce sample volume requirements while improving analytical performance. The preventative healthcare trend is particularly strong in emerging markets, where rising middle-class populations are investing more in personal wellness monitoring.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Stringent Regulatory Approvals Delay Market Entry for New Reagents</strong></p><p>
</p><p>The metabolite chemistry reagents market faces significant regulatory hurdles, particularly for novel diagnostic applications. Obtaining FDA clearance or CE marking for new reagent formulations typically requires 12-18 months of clinical validation studies and quality documentation, creating substantial barriers for smaller manufacturers. These regulatory requirements have intensified in recent years as authorities implement stricter performance standards for metabolic testing, with approximately 25% of new reagent submissions requiring additional data before approval. The resulting delays in product commercialization can impact market competitiveness and innovation cycles.</p><p>
</p><p style="text-align:center"><strong>Price Sensitivity in Emerging Markets Limits Premium Product Adoption</strong></p><p>
</p><p>While developed markets prioritize reagent performance and automation compatibility, cost remains the primary purchasing criterion in price-sensitive emerging economies. Many healthcare providers in these regions continue to use older generation reagents that may lack the precision of newer formulations but are significantly more affordable. This pricing pressure has limited the adoption of advanced metabolite chemistry reagents in markets that account for nearly 60% of the global population, despite having high metabolic disorder prevalence. Manufacturers face the challenge of balancing affordability with the quality standards required for accurate diagnostic results.</p><p>
</p><p style="text-align:center"><strong>Logistical Challenges in Cold Chain Distribution Affect Reagent Stability</strong></p><p>
</p><p>Many metabolite chemistry reagents require strict temperature control during transportation and storage, with some enzymatic formulations degrading rapidly if exposed to temperature excursions. Maintaining unbroken cold chains adds 15-20% to distribution costs in some regions and creates supply chain vulnerabilities, particularly in tropical climates. These challenges have led to measurable product quality issues, with approximately 3% of shipped reagents potentially compromised by improper handling. The industry continues to invest in more stable reagent formulations and advanced packaging solutions, but these improvements often come with increased production costs.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Expansion of Direct-to-Consumer Testing Opens New Distribution Channels</strong></p><p>
</p><p>The rapid growth of at-home health testing, with the global market projected to exceed $4 billion by 2027, creates significant opportunities for metabolite chemistry reagent manufacturers. Companies are developing consumer-friendly versions of professional-grade reagents for glucose monitoring, cholesterol testing, and other metabolic parameters. These products often incorporate simplified protocols and smartphone connectivity, allowing non-experts to perform accurate metabolic assessments. The convergence of diagnostic reagents with digital health platforms represents a major innovation frontier in personalized wellness management.</p><p>
</p><p style="text-align:center"><strong>Development of High-Sensitivity Reagents for Early Disease Detection</strong></p><p>
</p><p>Advances in reagent chemistry enable the detection of metabolic biomarkers at unprecedented sensitivity levels, facilitating earlier diagnosis of conditions like prediabetes and metabolic syndrome. New multiplex reagent panels can measure dozens of metabolites from minimal sample volumes, providing more comprehensive metabolic profiling. Researchers have identified over 200 clinically relevant metabolic biomarkers in recent years, with approximately 30% now having commercially available reagent-based detection methods. This innovation pipeline supports the transition from reactive to predictive healthcare models.</p><p>
</p><p style="text-align:center"><strong>Strategic Partnerships to Enhance Geographic Market Penetration</strong></p><p>
</p><p>Leading reagent manufacturers are actively forming alliances with regional diagnostic companies to strengthen their presence in high-growth emerging markets. These partnerships combine global R&amp;D expertise with local market knowledge and distribution networks, accelerating adoption of advanced metabolite testing solutions. Recent collaborations have focused on developing region-specific reagent formulations tailored to prevalent metabolic disorders and local testing preferences. Such strategic moves are particularly valuable in markets where healthcare infrastructure development outpaces the availability of advanced diagnostic technologies.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Supply Chain Vulnerabilities Impacting Reagent Availability</strong></p><p>
</p><p>The metabolite chemistry reagents market continues to face disruptions from global supply chain challenges affecting key raw materials. Specialty enzymes and biochemicals used in reagent formulations often have limited alternative sources, creating bottlenecks when geopolitical or logistical issues arise. Some manufacturers report lead times for certain raw materials extending beyond six months, forcing difficult choices between maintaining adequate inventory levels and managing working capital. These disruptions have contributed to periodic reagent shortages in clinical laboratories, potentially affecting patient care.</p><p>
</p><p style="text-align:center"><strong>Competition from Alternative Testing Methods</strong></p><p>
</p><p>While metabolite chemistry reagents remain essential for clinical diagnostics, they face increasing competition from alternative testing approaches. Mass spectrometry-based metabolomics offers superior analytical specificity for some applications, though at higher equipment costs. Meanwhile, continuous glucose monitors and other sensor-based technologies reduce reliance on reagent-based testing for certain metabolic parameters. Reagent manufacturers must continuously innovate to maintain their value proposition, particularly in applications where real-time or continuous monitoring provides clinical advantages.</p><p>
</p><p style="text-align:center"><strong>Workforce Shortages in Clinical Laboratories</strong></p><p>
</p><p>The global shortage of skilled medical laboratory professionals impacts metabolite chemistry testing throughput and quality. Many laboratories report unfilled positions exceeding 15% of their workforce needs, leading to increased testing turnaround times and potential errors in reagent handling. This shortage has prompted greater emphasis on reagent systems with simplified workflows and automated quality controls, but the transition requires capital investments that some laboratories cannot immediately afford. The situation is particularly acute in rural healthcare settings, where recruitment challenges are greatest.</p><p>
</p><p>
<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Glycometabolism Segment Dominates the Market Due to Rising Demand in Diabetes Monitoring</strong></p><p>
</p><p>The market is segmented based on type into:</p><p>
</p><p>Glycometabolism</p><p>
	</p><p>Subtypes: Glucose, Lactate, and others</p><p>Amino Acid Metabolism</p><p>Fatty Acid/Cholesterol Metabolism</p><p>Others</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Diabetes Segment Leads Due to High Prevalence of Metabolic Disorders Globally</strong></p><p>
</p><p>The market is segmented based on application into:</p><p>
</p><p>Diabetes</p><p>Obesity</p><p>Other metabolic disorders</p><p>
<strong>By End User</strong></p><p>
</p><p><strong>Hospitals &amp; Diagnostic Centers Hold Largest Share Due to Increasing Patient Testing Volumes</strong></p><p>
</p><p>The market is segmented based on end user into:</p><p>
</p><p>Hospitals &amp; diagnostic centers</p><p>Research laboratories</p><p>Pharmaceutical &amp; biotechnology companies</p><p>Academic institutions</p><p>

</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Innovation and Strategic Expansion Drive Market Competition</strong></p><p>
</p><p>The global <strong>Metabolite Chemistry Reagents market</strong> is characterized by a mix of established pharmaceutical giants and specialized diagnostic companies, all competing to enhance their market position. <strong>The top five manufacturersâ€”Merck, BioVision, Thermo Fisher Scientific, BD, and Abbottâ€”collectively hold around 50% of the global market share as of 2024</strong>, indicating strong consolidation among key players. This dominance is largely due to their extensive R&amp;D capabilities, diversified product offerings, and robust distribution networks.</p><p>
</p><p>Among these, <strong>Merck KGaA</strong> and <strong>Thermo Fisher Scientific</strong> stand out for their advanced metabolite profiling reagents and wide application in clinical diagnostics. With operations spanning North America, Europe, and Asia, these companies benefit from economies of scale and high brand recognition in research institutions and diagnostic labs.</p><p>
</p><p>Meanwhile, mid-sized players like <strong>BioVision</strong> and <strong>Pointe Scientific</strong> are gaining traction by focusing on niche applications, such as glycometabolism and amino acid metabolism reagents. Their specialized product lines cater to emerging research needs in metabolic diseases, allowing them to carve out competitive advantages.</p><p>
</p><p>Strategic acquisitions and collaborations are further intensifying the competition. For instance, <strong>Abbott Laboratories</strong> recently expanded its metabolite assay portfolio through partnerships with academic research centers, reinforcing its position in diabetes diagnosticsâ€”a segment that accounts for nearly <strong>50% of metabolite reagent applications</strong>.</p><p>
<strong>List of Key Metabolite Chemistry Reagents Companies Profiled</strong></p><p>
</p><p>Merck KGaA (Germany)</p><p>BioVision, Inc. (U.S.)</p><p>Thermo Fisher Scientific Inc. (U.S.)</p><p>BD (Becton, Dickinson and Company) (U.S.)</p><p>Abbott Laboratories (U.S.)</p><p>Kerafast, Inc. (U.S.)</p><p>Beijing Strong Biotechnologies (China)</p><p>Pointe Scientific, Inc. (U.S.)</p><p>Luxcel Biosciences (Ireland)</p><p>Randox Laboratories (U.K.)</p><p>BioSino Bio-Technology (China)</p><p>NITTO BOSEKI CO., LTD. (Japan)</p><p>

</p><p>
<strong>METABOLITE CHEMISTRY REAGENTS MARKET TRENDS</strong></p><p>
<strong>Growing Prevalence of Metabolic Disorders Drives Demand for Specialized Reagents</strong></p><p>
</p><p>The global metabolite chemistry reagents market is experiencing significant growth due to the rising incidence of metabolic disorders such as diabetes, obesity, and cardiovascular diseases. The World Health Organization estimates that over <strong>422 million people</strong> worldwide suffer from diabetes, fueling demand for accurate diagnostic solutions. Glycometabolism reagents account for nearly <strong>50%</strong> of market share, as glucose testing remains a critical aspect of diabetes management. Recent technological advancements in mass spectrometry and chromatography have improved reagent sensitivity, enabling earlier disease detection and more precise monitoring of metabolic pathways.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Automation and High-Throughput Screening</strong></p><p>
</p><p>Laboratories are increasingly adopting automated platforms for metabolic profiling, driving demand for standardized reagent kits compatible with robotic systems. The shift toward high-throughput screening in pharmaceutical research and clinical diagnostics has led to a <strong>15-20% annual growth</strong> in pre-formulated reagent mixtures. These ready-to-use solutions reduce human error and improve reproducibility, particularly in large-scale metabolic studies. Manufacturers are responding by developing stable, lyophilized reagents with extended shelf lives that maintain consistency across automated workflows.</p><p>
<strong>Expansion of Point-of-Care Testing</strong></p><p>
</p><p>The decentralization of diagnostic testing is creating new opportunities in the metabolite reagent market, with point-of-care devices projected to capture <strong>30%</strong> of the diagnostic segment by 2030. Compact analyzers now enable quantitative metabolite measurements in physician offices and remote clinics, requiring reagents optimized for stability at ambient temperatures. This trend aligns with growing healthcare accessibility initiatives in emerging markets, where reagent manufacturers are developing cost-effective solutions without compromising analytical performance. Recent innovations include microfluidic-compatible reagents that deliver lab-grade accuracy from fingerstick blood samples.</p><p>
<strong>Biomarker Discovery and Precision Medicine</strong></p><p>
</p><p>Advances in metabolomics research are uncovering novel metabolic biomarkers for disease stratification and therapeutic monitoring, creating demand for specialized reagents. Pharmaceutical companies now allocate <strong>25-30%</strong> of their R&amp;D budgets to metabolic pathway analysis during drug development. This has spurred innovation in isotope-labeled internal standards and derivatization reagents that improve mass spec detection limits. Meanwhile, the push toward personalized nutrition and metabolic therapy is driving adoption of reagent panels that profile individual metabolic fingerprints, enabling tailored interventions based on amino acid and lipid metabolism profiles.</p><p>
</p><p>
<strong>Regional Analysis: Metabolite Chemistry Reagents Market</strong></p><p>
</p><p><strong>North America</strong></p><p>
North America currently dominates the global metabolite chemistry reagents market, holding approximately <strong>45%</strong> of the total market share, primarily driven by the United States. The region's leadership stems from its <strong>advanced healthcare infrastructure</strong>, strong research &amp; development initiatives, and high prevalence of metabolic disorders like diabetes and obesity. Major industry players such as Thermo Fisher Scientific, Merck, and Abbott maintain strong operations in this region, further fueling market growth. Regulatory agencies like the FDA enforce strict quality standards, ensuring the reliability of diagnostic reagents. Despite market maturity, steady demand persists due to increasing chronic disease burdens and continuous investments in precision medicine and metabolomics research.</p><p>
</p><p><strong>Europe</strong></p><p>
Europe accounts for <strong>25%</strong> of the global metabolite chemistry reagents market, supported by rigorous regulatory frameworks like the EU IVDR (In Vitro Diagnostic Regulation). Countries such as Germany, France, and the U.K. lead in adoption due to well-established diagnostic laboratories and growing emphasis on preventive healthcare. However, pricing pressures from universal healthcare systems and slower approval processes for new reagents slightly hinder market expansion. Collaborative research between academic institutions and pharmaceutical companies drives innovation, particularly in glycometabolism and lipid metabolism reagents, addressing the rising cases of diabetes and cardiovascular diseases.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
The <strong>fastest-growing</strong> region, Asia-Pacific, benefits from rapid economic development, expanding healthcare access, and increasing government investments in diagnostics. China and India are pivotal markets due to large patient pools with metabolic disorders and improving hospital infrastructure. Local manufacturers like Beijing Strong Biotechnologies and Shenzhen Bioeasy Biotechnology are gaining traction, though global brands still lead in high-end products. Cost sensitivity remains a challenge, but rising awareness and urbanization are shifting preferences toward reliable reagent solutions. Japan and South Korea contribute significantly through technological advancements and strong biotechnology sectors.</p><p>
</p><p><strong>South America</strong></p><p>
South America shows <strong>moderate growth</strong>, with Brazil and Argentina as key markets. Economic instability and limited healthcare budgets constrain widespread adoption of premium reagents, though increasing diabetes prevalence creates demand. The market relies heavily on imports due to underdeveloped local manufacturing capabilities. Regulatory harmonization efforts across the region aim to streamline approvals, but inconsistent enforcement and logistical challenges persist. In the long term, partnerships with global suppliers may enhance accessibility to advanced diagnostic solutions.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
This region remains an <strong>emerging market</strong>, with growth concentrated in affluent Gulf Cooperation Council (GCC) countries like Saudi Arabia and the UAE. Government initiatives to modernize healthcare infrastructure and combat metabolic diseases drive demand, though low penetration in rural areas limits overall market potential. Africa faces challenges such as inadequate funding and a fragmented healthcare landscape, but increasing private-sector involvement offers opportunities for market players. Local production is minimal, with most reagents imported from Europe and North America.</p><p>

<strong>Report Scope</strong></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Metabolite Chemistry Reagents, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Metabolite Chemistry Reagents companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Metabolite Chemistry Reagents Market?</strong></p><p>
</p><p><strong>-&gt;</strong> The global Metabolite Chemistry Reagents market was valued at <strong>USD 116 million in 2024</strong> and is projected to reach <strong>USD 140 million by 2032</strong>, growing at a CAGR of 2.7% during the forecast period.</p><p>
<strong>Which key companies operate in Global Metabolite Chemistry Reagents Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>Merck, BioVision, Thermo Fisher Scientific, BD, Abbott, Kerafast, and Beijing Strong Biotechnologies</strong>, among others. The top five manufacturers hold approximately 50% of the global market share.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include <strong>rising prevalence of metabolic disorders, increasing diabetes and obesity cases, and advancements in diagnostic technologies</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; North America</strong> is the largest market with a share of about 45%, followed by <strong>Europe</strong> with 25%. The United States remains the dominant country-level market.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include <strong>development of high-sensitivity reagents, automation in diagnostic testing, and increasing adoption of point-of-care testing solutions</strong>.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/297445/metabolite-chemistry-reagents-market">
            https://www.24chemicalresearch.com/reports/297445/metabolite-chemistry-reagents-market</a></b></div><br>
            <b>Table of Content:</b><p>1 Introduction to Research & Analysis Reports<br />
 1.1 Metabolite Chemistry Reagents Market Definition<br />
 1.2 Market Segments<br />
 1.2.1 Segment by Type<br />
 1.2.2 Segment by Application<br />
 1.3 Global Metabolite Chemistry Reagents Market Overview<br />
 1.4 Features & Benefits of This Report<br />
 1.5 Methodology & Sources of Information<br />
 1.5.1 Research Methodology<br />
 1.5.2 Research Process<br />
 1.5.3 Base Year<br />
 1.5.4 Report Assumptions & Caveats<br />
2 Global Metabolite Chemistry Reagents Overall Market Size<br />
 2.1 Global Metabolite Chemistry Reagents Market Size: 2024 VS 2032<br />
 2.2 Global Metabolite Chemistry Reagents Market Size, Prospects & Forecasts: 2020-2032<br />
 2.3 Global Metabolite Chemistry Reagents Sales: 2020-2032<br />
3 Company Landscape<br />
 3.1 Top Metabolite Chemistry Reagents Players in Global Market<br />
 3.2 Top Global Metabolite Chemistry Reagents Companies Ranked by Revenue<br />
 3.3 Global Metabolite Chemistry Reagents Revenue by Companies<br />
 3.4 Global Metabolite Chemistry Reagents Sales by Companies<br />
 3.5 Global Metabolite Chemistry Reagents Price by Manufacturer (2020-2025)<br />
 3.6 Top 3 and Top 5 Metabolite Chemistry Reagents Companies in Global Market, by Revenue in 2024<br />
 3.7 Global Manufacturers Metabolite Chemistry Reagents Product Type<br />
 3.8 Tier 1, Tier 2, and Tier 3 Metabolite Chemistry Reagents Players in Global Market<br />
 3.8.1 List of Global Tier 1 Metabolite Chemistry Reagents Companies<br />
 3.8.2 List of Global Tier 2 and Tier 3 Metabolite Chemistry Reagents Companies<br />
4 Sights by Product<br />
 4.1 Overview<br />
 4.1.1 Segmen</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/297445/metabolite-chemistry-reagents-market">
            https://www.24chemicalresearch.com/reports/297445/metabolite-chemistry-reagents-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>